67Cu-based CuNeo therapeutic - NUCLIDIUM
Alternative Names: 67Cu-based CuNeo™ therapeuticLatest Information Update: 28 Apr 2026
At a glance
- Originator NUCLIDIUM
- Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Breast cancer; Colorectal cancer; Gastric cancer
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for phase-I development in Breast-cancer in Unknown
- 28 Apr 2026 No recent reports of development identified for phase-I development in Colorectal-cancer in Unknown
- 28 Apr 2026 No recent reports of development identified for phase-I development in Gastric-cancer in Unknown